On January 27, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib (Jaypirca, Eli Lilly and Company), for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.…
On January 19, the U.S. Food and Drug Administration (FDA) announced it has approved bruton tyrosine kinase (BTK), zanubrutinib (Brukinsa, BeiGene), for chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL). BTK is a protein critical for the growth and survival of B-cells. BTK…
On December 22, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific antibody, for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two or more…
December 23, 2022 – It is with great sadness that the Lymphoma Research Foundation (LRF) shares news of the passing of Errol M. Cook, a two-time Chair of the LRF Board of Directors and current Director Emeritus. With his devoted…
No parent should ever have to go through the excruciating experience of losing a child. When Ellen M. Walker lost her only son, Paul, to lymphoma in 2012, she was devastated. She channeled her grief into creating The Paul Foundation…
Roy Bridges has the type of life story you need to read to believe. Starting on a farm in rural northeast Georgia, it includes attending the U.S. Air Force Academy; surviving 226 Vietnam combat missions; serving as a staff officer…
Where Are They Now? Paolo Strati, MD When did you become interested in the study of medicine? In lymphoma specifically? My pathway to medicine has not been linear nor as smooth as you would think, as pretty much nothing in…